Banque Cantonale Vaudoise lessened its stake in Incyte Co. (NASDAQ:INCY – Get Rating) by 12.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,308 shares of the biopharmaceutical company’s stock after selling 1,008 shares during the period. Banque Cantonale Vaudoise’s holdings in Incyte were worth $587,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Signaturefd LLC raised its position in Incyte by 25.4% during the 4th quarter. Signaturefd LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 361 shares during the last quarter. PGGM Investments bought a new position in Incyte during the 3rd quarter valued at approximately $20,554,000. IFP Advisors Inc raised its position in Incyte by 3.7% during the 3rd quarter. IFP Advisors Inc now owns 17,318 shares of the biopharmaceutical company’s stock valued at $1,178,000 after purchasing an additional 615 shares during the last quarter. Canada Pension Plan Investment Board raised its position in Incyte by 10.1% during the 3rd quarter. Canada Pension Plan Investment Board now owns 440,492 shares of the biopharmaceutical company’s stock valued at $29,354,000 after purchasing an additional 40,400 shares during the last quarter. Finally, ExodusPoint Capital Management LP bought a new position in Incyte during the 3rd quarter valued at approximately $1,398,000. Institutional investors own 95.08% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research analysts have commented on INCY shares. Morgan Stanley upped their price target on Incyte from $76.00 to $77.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 12th. JMP Securities decreased their target price on Incyte from $113.00 to $93.00 in a research report on Thursday, May 4th. Credit Suisse Group increased their target price on Incyte from $95.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, February 16th. Piper Sandler reissued an “overweight” rating and issued a $100.00 target price on shares of Incyte in a research report on Wednesday, February 8th. Finally, BMO Capital Markets decreased their target price on Incyte from $75.00 to $70.00 in a research report on Wednesday, May 3rd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $81.50.
Incyte Stock Performance
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company was founded in April 1991 and is headquartered in Wilmington, DE.
- Get a free copy of the StockNews.com research report on Incyte (INCY)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY – Get Rating).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.